These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3528891)

  • 1. Desamino-D-arginine-vasopressin (DDAVP) in Alzheimer's disease.
    Peabody CA; Davies H; Berger PA; Tinklenberg JR
    Neurobiol Aging; 1986; 7(4):301-3. PubMed ID: 3528891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desamino arginine vasopressin (DDAVP) as a diagnostic agent.
    Somerfield SD; Hocken AG
    N Z Med J; 1977 Nov; 86(600):472-3. PubMed ID: 343010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desmopressin in nocturnal enuresis.
    Aladjem M; Wohl R; Boichis H; Orda S; Lotan D; Freedman S
    Arch Dis Child; 1982 Feb; 57(2):137-40. PubMed ID: 7039520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of 1-deamino-8-D-arginine vasopressin after various routes of administration in healthy volunteers.
    Fjellestad-Paulsen A; Höglund P; Lundin S; Paulsen O
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):177-82. PubMed ID: 8435898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desmopressin for nocturnal enuresis: urinary osmolality and response.
    Folwell AJ; Macdiarmid SA; Crowder HJ; Lord AD; Arnold EP
    Br J Urol; 1997 Sep; 80(3):480-4. PubMed ID: 9313673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between the action of arginine vasopressin and responsiveness to oral desmopressin in older men: a pilot study.
    Johnson TM; Burridge A; Issa MM; Miller M; Tang T; Ouslander JG
    J Am Geriatr Soc; 2007 Apr; 55(4):562-9. PubMed ID: 17397435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DDAVP in childhood nocturnal enuresis.
    Tuvemo T
    Acta Paediatr Scand; 1978 Nov; 67(6):753-5. PubMed ID: 568870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desmopressin in the management of nocturnal enuresis in children: a double-blind study.
    Birkásová M; Birkás O; Flynn MJ; Cort JH
    Pediatrics; 1978 Dec; 62(6):970-4. PubMed ID: 366538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study on mechanisms of a haemostatic effect of 1 deamino-8-D-arginine vasopressin (desmopressin) in uraemic patients.
    Malyszko J; Pietraszek M; Buczko W; Mysliwiec M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(2):319-24. PubMed ID: 1697836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daytime functional bladder capacity as a predictor of response to desmopressin in monosymptomatic nocturnal enuresis.
    Eller DA; Austin PF; Tanguay S; Homsy YL
    Eur Urol; 1998; 33 Suppl 3():25-9. PubMed ID: 9599733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of DDAVP (1-desamino-8-D-arginine vasopressin) in children with central diabetes insipidus (author's transl)].
    Tomita M; Nakagawa S; Saito N; Sakurada N; Nonoda A
    Horumon To Rinsho; 1979 Jun; 27(6):681-5. PubMed ID: 466837
    [No Abstract]   [Full Text] [Related]  

  • 12. DDAVP (1-desamino-8-D-arginine-vasopressin) treatment of central diabetes insipidus--mechanism of prolonged antidiuresis.
    Seif SM; Zenser TV; Ciarochi FF; Davis BB; Robinson AG
    J Clin Endocrinol Metab; 1978 Mar; 46(3):381-8. PubMed ID: 221517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DDAVP and urine osmolality in refractory enuresis.
    Dimson SB
    Arch Dis Child; 1986 Nov; 61(11):1104-7. PubMed ID: 3539030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of desmopressin (DDAVP) in nocturnal urinary frequency in the female.
    Hilton P; Stanton SL
    Br J Urol; 1982 Jun; 54(3):252-5. PubMed ID: 7049302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous and intranasal administration of 1-deamino-8-d-arginine vasopressin in the assessment of renal concentration capacity.
    Tryding N; Sterner G; Berg B; Harris A; Lundin S
    Nephron; 1987; 45(1):27-30. PubMed ID: 3808145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central diabetes insipidus in children. Antidiuretic effect and pharmacokinetics of intranasal and peroral 1-deamino-8-D-arginine vasopressin.
    Fjellestad-Paulsen A; Tubiana-Rufi N; Harris A; Czernichow P
    Acta Endocrinol (Copenh); 1987 Jul; 115(3):307-12. PubMed ID: 3618082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
    Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DDAVP in young enuretic patients: a double-blind trial.
    Ferrie BG; MacFarlane J; Glen ES
    Br J Urol; 1984 Aug; 56(4):376-8. PubMed ID: 6398716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, pharmacodynamics, long-term efficacy and safety of oral 1-deamino-8-D-arginine vasopressin in adult patients with central diabetes insipidus.
    Lam KS; Wat MS; Choi KL; Ip TP; Pang RW; Kumana CR
    Br J Clin Pharmacol; 1996 Sep; 42(3):379-85. PubMed ID: 8877030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasopressin analog DDAVP in the treatment of diabetes insipidus.
    Lee WP; Lippe BM; La Franchi SH; Kaplan SA
    Am J Dis Child; 1976 Feb; 130(2):166-9. PubMed ID: 766613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.